专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022046840A1 HYBRID ALLOSTERIC RECEPTOR-ENGINEERED STEM CELLS 审中-公开
公开(公告)号：WO2022046840A1
公开(公告)日：2022-03-03
申请号：PCT/US2021/047452
申请日：2021-08-25
申请人： ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA , WON, Young-Wook , CHA, Byeong-Hyun , BULL, David A.
发明人： WON, Young-Wook , CHA, Byeong-Hyun , BULL, David A.
IPC分类号： C12N5/10 , C07K14/00
摘要： Described herein are mesenchymal stem cells (MCS) expressing hybrid allosteric receptors (HAR) that are responsive to stromal cell-derived factor 1 alpha (SDF-1α) secreted from acutely infarcted myocardium. Binding of SDF-1α to CXCR4 activates the co-stimulatory signals, bone morphogenetic protein 2 type II receptor (BMP2R2) and BMP type I receptor (ALK3), in order to accelerate the differentiation into cardiomyocytes. HAR-MSC CXCR4 differentiates into cardiomyocytes through Smad1/5 phosphorylation induced by the BMP2 signaling. In acute myocardial infarction (AMI) models, HAR-MSC CXCR4 treatment leads to the functional improvements by facilitated differentiation and increased cytokine secretion. HAR-MSC CXCR4 cells can be used for the treatment of AMI.

2. 发明申请

WO2022046840A8 HYBRID ALLOSTERIC RECEPTOR-ENGINEERED STEM CELLS 审中-公开
公开(公告)号：WO2022046840A8
公开(公告)日：2022-03-03
申请号：PCT/US2021/047452
申请日：2021-08-25
申请人： ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA , WON, Young-Wook , CHA, Byeong-Hyun , BULL, David A.
发明人： WON, Young-Wook , CHA, Byeong-Hyun , BULL, David A.
IPC分类号： C12N5/10 , C07K14/00 , A61K35/28 , A61K35/545 , A61K48/005 , A61P9/00 , C07K14/70517 , C07K14/71 , C07K14/7158 , C12N2501/155 , C12N2501/20 , C12N2510/00 , C12N5/0663
摘要： Described herein are mesenchymal stem cells (MCS) expressing hybrid allosteric receptors (HAR) that are responsive to stromal cell-derived factor 1 alpha (SDF-1α) secreted from acutely infarcted myocardium. Binding of SDF-1α to CXCR4 activates the co-stimulatory signals, bone morphogenetic protein 2 type II receptor (BMP2R2) and BMP type I receptor (ALK3), in order to accelerate the differentiation into cardiomyocytes. HAR-MSC CXCR4 differentiates into cardiomyocytes through Smad1/5 phosphorylation induced by the BMP2 signaling. In acute myocardial infarction (AMI) models, HAR-MSC CXCR4 treatment leads to the functional improvements by facilitated differentiation and increased cytokine secretion. HAR-MSC CXCR4 cells can be used for the treatment of AMI.

3. 发明申请

WO2013109983A1 HIGH MOLECULAR WIEGHT ARGININE-GRAFTED BIOREDUCIBLE POLYMERS 审中-公开
标题翻译：高分子量ARGININE-GRAFTED生物可降解聚合物
公开(公告)号：WO2013109983A1
公开(公告)日：2013-07-25
申请号：PCT/US2013/022294
申请日：2013-01-18
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , KIM, Sung Wan , NAM, Hye Yeong , NAM, Kihoon , BULL, David, A.
发明人： KIM, Sung Wan , NAM, Hye Yeong , NAM, Kihoon , BULL, David, A.
IPC分类号： A61K47/48 , A61K47/30 , A61K48/00
CPC分类号： A61K48/0041 , A61K47/34 , A61K47/595 , C12N15/111 , C12N15/85 , C12N2310/14 , C12N2320/32
摘要： The polymeric carrier for delivering nucleic acid material to a cell is provided herein. The polymeric carrier can include a dendrimer group having 2 to 8 termini, each of the termini having an arginine-grafted bioreducible polymer attached thereto. In one embodiment, only a porition of the termini can have an arginine-grafted bioreducible polymer attached thereto.
摘要翻译：本文提供了用于将核酸材料递送至细胞的聚合物载体。聚合物载体可以包括具有2至8个末端的树枝状聚合物基团，每个末端具有连接到其上的精氨酸接枝的生物还原性聚合物。在一个实施方案中，只有末端的末端可以具有连接到其上的精氨酸接枝的生物可还原性聚合物。

4. 发明申请

WO2013003595A1 BROWN FAT CELL COMPOSITIONS AND METHODS 审中-公开
标题翻译：棕色脂肪细胞组成和方法
公开(公告)号：WO2013003595A1
公开(公告)日：2013-01-03
申请号：PCT/US2012/044651
申请日：2012-06-28
申请人： BIORESTORATIVE THERAPIES, INC. , SILVA, Francisco, Javier , WEINREB, Mark , PATEL, Amit, N. , BULL, David, A.
发明人： SILVA, Francisco, Javier , WEINREB, Mark , PATEL, Amit, N. , BULL, David, A.
IPC分类号： C12N5/077 , C12N5/0775
CPC分类号： C12N5/0667 , A61K35/28 , A61K35/35 , C12N5/0653 , C12N2500/84 , C12N2500/98 , C12N2501/01 , C12N2501/02 , C12N2501/33 , C12N2501/385 , C12N2501/39 , C12N2501/395 , C12N2506/1384 , G01N33/502 , G01N33/5044 , Y02A50/395
摘要： Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.
摘要翻译：开发和使用细胞系，如干细胞系，用于治疗或化妆品使用的方法。在一个实施方案中，细胞系用于治疗广泛范围的退行性和代谢性疾病，包括但不限于肥胖症，糖尿病，高血压和心脏不足。还描述了使用这种细胞系筛选在调节各种过程中发挥作用的化合物的方法。

5. 发明申请

WO2008057481A1 VENTRICULAR ASSIST DEVICE CAPABLE OF IMPLANTATION OF STEM CELLS 审中-公开
标题翻译：能够植入干细胞的血管辅助装置
公开(公告)号：WO2008057481A1
公开(公告)日：2008-05-15
申请号：PCT/US2007/023251
申请日：2007-11-05
申请人： THE UNIVERSITY OF UTAH , BULL, David, A. , CONNORS, Rafe, C. , ERICKSON, Harold, M. , YOCKMAN, James , KIM, Sung, Wan
发明人： BULL, David, A. , CONNORS, Rafe, C. , ERICKSON, Harold, M. , YOCKMAN, James , KIM, Sung, Wan
IPC分类号： A61M1/10 , C12N5/06 , A61M1/12
CPC分类号： A61K35/34 , A61B8/12 , A61M1/1001 , A61M1/1006 , A61M1/1008 , A61M1/12 , A61M1/122 , A61M1/127 , A61M1/3472 , A61M1/3618 , A61M1/3621 , A61M1/3667 , A61M1/3689 , C12N5/0662
摘要： A biologic ventricular assist device that also has the capability to capture, grow, and administer stem cells to regenerate and restore damaged myocardium in the heart. The device works in conjunction with a traditional ventricular assist device and possesses an additional external path or tube that is in-line with the path of the ventricular assist device. The external path allows for the administration of stem cells, genes, genetically modified cells or other therapeutic biologic or pharmacologic agents, as well as leading to a stem cell collecting accessory (14) that captures circulating stem cells. The stem cell collecting accessory is also associated with a chamber (39) for culturing the captured stem cells. The cultured stem cells can be delivered back to the heart by an electro-mechanical or ultrasound/echocardiographic delivery system that runs through the external path back into the ventricular assist device and allows for the delivery of the stem cells, or other therapeutic biologic or pharmacologic agents, directly into the internal chambers of the heart. Administering the stem cells, genes, genetically modified cells or other therapeutic biologic or pharmacologic agents, either alone or in combination, to the heart allows the myocardium to regenerate and repair itself even while the heart is attached to the ventricular assist device, ultimately allowing the heart to regenerate, recover and allow the VAD to be removed.
摘要翻译：一种生物心室辅助装置，其还具有捕获，生长和施用干细胞以再生和恢复心脏中损伤的心肌的能力。该装置与传统的心室辅助装置一起工作，并且具有与心室辅助装置的路径一致的额外的外部路径或管。外部途径允许施用干细胞，基因，遗传修饰的细胞或其他治疗生物或药理学试剂，以及导致捕获循环干细胞的干细胞收集附件（14）。干细胞收集附件还与用于培养所捕获的干细胞的室（39）相关联。培养的干细胞可以通过机电或超声/超声心动图输送系统递送回心脏，该系统通过外部路径返回到心室辅助装置，并允许输送干细胞或其他治疗性生物学或药理学代理人，直接进入内心的内心。将心脏单独或组合的干细胞，基因，遗传修饰的细胞或其他治疗性生物或药理学剂施用于心脏，即使在心脏附着于心室辅助装置时也能使心肌再生和修复自身，最终允许心脏再生，恢复并允许VAD被去除。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式